Cipepofol Anesthesia Induction Improves Hemodynamic Stability for High-Risk CV Patients: Study

A new study published in the Journal of American Medical Association found that cipepofol demonstrated superior hemodynamic stability compared to propofol when used at equipotent doses and similar anesthesia depths in patients with aortic stenosis (AS). These findings suggest that cipepofol may be a safer alternative induction agent for patients with high cardiovascular risk.

For individuals with severe aortic stenosis, transcatheter aortic valve replacement (TAVR) is a less intrusive option than surgical aortic valve replacement. A frequent consequence that might arise from the induction of anesthesia to the initial surgical incision is arterial hypotension, especially in elderly patients whose preoperative physical condition is already weakened.

Cipepofol, sometimes called ciprofol, is a short-acting derivative of propofol that increases the γ-aminobutyric acid type A receptor's sensitivity. Thus, to determine if cipepofol performs better than propofol in preserving postinduction hemodynamic stability in patients with AS, Tingting Ni and team carried out this investigation.

From June 29, 2023, until July 8, 2024, this clinical study was carried out at Zhejiang University School of Medicine's Second Affiliated Hospital in China. Inclusion criteria were patients with AS who were planned for transcatheter aortic valve replacement (TAVR). Propofol or cipepofol was administered as anesthesia induction drugs at equipotent dosages to participants in a 1:1 randomized trial. The area under the curve (AUC) of the mean arterial pressure (MAP) variation from baseline during the first 15 minutes after induction was the main result.